Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Iron showdown: IV vs pills after heart attack

NCT ID NCT05309499

Disease control Sponsor: Kazan State Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving iron through a vein (IV) works better than iron pills for improving heart pumping function in people who recently had a heart attack and also have low iron. About 300 adults took part, receiving either IV iron or oral iron. The main goal was to see if heart wall motion improved, which reflects better heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ferric carboxymaltose (IV iron) and ferrous sulphate (oral iron)
What this could lead to
If IV iron works better, it could become a standard way to help heart attack patients with low iron recover stronger heart function.
What could go wrong
This is a completed early-stage study with 298 people. The results may not apply to all patients, and iron therapy carries risks like allergic reactions or iron overload.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

298 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥18 years of age) able to provide informed consent. Hospitalized myocardial infarction patients (that diagnosed according to Fourth Universal Definition of myocardial infarction and myocardial injury, ESC 2018) with hypokinesia or akinesia in at least two connected left ventricular segments according to echocardiography results obtained within the first 24 hours after myocardial infarction occurs. * Hemoglobin \>9.0 g/dL and \<15,0 g/dl and serum iron \<12 µmol/l on screening visit. * Serum ferritin \<100 μg/L, or 100-299 μg/L when transferrin saturation \<20%. Exclusion Criteria: * Known hypersensitivity reaction to any component of ferric carboxymaltose. * History of acquired iron overload, or the recent receipt (within 3 months) of erythropoietin stimulating agent, i.v. iron therapy, or blood transfusion. * Heart failure Killip class II-IV on screening visit. * Current or planned mechanical circulatory support or heart transplantation. * Hemodialysis or peritoneal dialysis (current or planned within the next 6 months). * Documented liver disease, or active hepatitis (i.e. alanine transaminase or aspartate transaminase \>3 times the upper limit of normal range). * Current or recent (within 3 years) malignancy with exception of basal cell carcinoma or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia. * Active gastrointestinal bleeding. * Female participant of child-bearing potential who is pregnant, lactating, or not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication. * Inability to return for follow up visits within the necessary period of time.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Iron-deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

iron deficiency anemia myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Iron-deficiency Myocardial infarction

Contacts and locations

Locations

  • Kazan State Medical Universety

    Kazan', Tatarstan Republic, 420012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.